Stammdaten
Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.
Unternehmen & Branche
| Name | Kalaris Therapeutics, Inc. |
|---|---|
| Ticker | KLRS |
| CIK | 0001754068 |
| Boerse | US |
| Sektor | Healthcare |
| Industrie | Biotechnology |
| SIC | 2836 · Biological Products, (No Diagnostic Substances) |
Wertpapier & Kennzahlen
| CUSIP | – |
|---|---|
| ISIN | – |
| Typ | Common Stock |
| Marktkapitalisierung | 107,4 Mio. USD |
| Beta | 0,18 |
| Dividendenrendite | 0,00 % |
Externe Quellen: SEC EDGAR » · FMP-Profil » · Yahoo Finance »
Finanzkennzahlen (SEC XBRL)
| Periode | Filing | Umsatz | Nettoergebnis | EPS | Aktiva | Eigenkapital |
|---|---|---|---|---|---|---|
| 2025-12-31 | 10-K | -43,438,000 | -2.85 | 121,736,000 | 78,814,000 | |
| 2025-09-30 | 10-Q | -11,894,000 | -0.64 | 81,175,000 | 41,865,000 | |
| 2025-06-30 | 10-Q | -11,350,000 | -0.61 | 92,842,000 | 53,115,000 | |
| 2025-03-31 | 10-Q | -10,196,000 | -2.52 | 103,092,000 | 63,874,000 | |
| 2024-12-31 | 10-K | -69,167,000 | -51.77 | 6,162,000 | -96,616,000 | |
| 2024-09-30 | 10-Q | -38,084,000 | -28.16 | 122,530,000 | -89,380,000 | |
| 2024-06-30 | 10-Q | -5,650,000 | -4.26 | 130,987,000 | -51,527,000 | |
| 2024-03-31 | 10-Q | -3,407,000 | -2.60 | 144,143,000 | -47,540,000 | |
| 2023-12-31 | 10-K | -190,418,000 | -42.09 | 190,796,000 | -45,017,000 | |
| 2023-09-30 | 10-Q | -44,272,000 | -0.39 | 248,312,000 | 195,334,000 | |
| 2023-06-30 | 10-Q | -45,267,000 | -0.48 | 282,692,000 | 229,113,000 | |
| 2023-03-31 | 10-Q | -41,183,000 | -0.44 | 244,044,000 | 193,532,000 | |
| 2022-12-31 | 10-K | -168,710,000 | -2.20 | 277,079,000 | 224,519,000 | |
| 2022-09-30 | 10-Q | -42,072,000 | -0.50 | 293,698,000 | 253,226,000 | |
| 2022-06-30 | 10-Q | -44,639,000 | -0.69 | 199,995,000 | 158,137,000 | |
| 2022-03-31 | 10-Q | -43,863,000 | -0.69 | 231,090,000 | 191,675,000 | |
| 2021-12-31 | 10-K | -171,962,000 | -2.74 | 286,594,000 | 225,266,000 | |
| 2021-09-30 | 10-Q | -45,510,000 | -0.72 | 316,530,000 | 267,304,000 | |
| 2021-06-30 | 10-Q | -37,588,000 | -0.60 | 327,511,000 | 302,469,000 | |
| 2021-03-31 | 10-Q | -30,923,000 | 351,281,000 | 330,369,000 |
Fondsaktivität (Vorquartalsvergleich)
Keine Fondsdaten für dieses Unternehmen vorhanden.
Insider-Transaktionen (12 Monate)
| Datum | Insider | Rolle | Typ | Stückzahl | Kurs | Wert (USD) | Δ | Trend |
|---|---|---|---|---|---|---|---|---|
| 2025-12-18 | AKKARAJU SRINIVAS | Director, 10% Owner | Open Market Purchase | 479,847 | 10.42 | 5,000,005.74 | +100,0% |
Top-Fondshalter
Keine Fondsdaten zu dieser Aktie vorhanden.